Inclusion body myositis

Current Opinion in Rheumatology

Volumn 14, Issue 6, 2002, Pages 653-657

  Tawil, Rabi ^a,b   Griggs, Robert C ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; OXANDROLONE; PREDNISONE;

CELL MIGRATION; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; ELECTROMYOGRAPHY; ELECTRON MICROSCOPY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; MUSCLE BIOPSY; MUSCLE CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; SEX FACTORS; TREATMENT OUTCOME;

EID: 0036838994     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200211000-00004     Document Type: Review

References (36)

1. Yunis EJ, Samaha FJ: Inclusion body myositis. Lab Invest 1971, 25:240-248.
2. Phillips BA, Zilko PJ, Mataglia FL: Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000, 23:970-972.
3. Badrising UA, Maat-Schieman M, van Duinen SG, et al.: Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000, 55:1385-1387.
4. Griggs RC, Askanas V, DiMauro S, et al.: Inclusion body myositis and myopathies. Ann Neurol 1995, 38:705-713.
5. Amato AA, Gronseth GS, Jackson CE, et al.: Inclusion body myositis: clinical and pathologic boundaries. Ann Neurol 1996, 40:581-586.
6. Lotz B, Engel AG, Nishino H, et al.: Inclusion body myositis: observations in 40 patients. Brain 1989, 112:727-747.
7. Felice KJ, North WA: Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine 2001, 80:320-327.
8. Koffman BM, Rugiero M, Dalakas MC: Immune-mediated condition and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998, 21:115-117.
9. Brouwer R, Hengstman GJD, Vree Egberts W, et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60:116-123.
10. Buchbinder R, Forbes A, Hall S, et al.: Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 2001, 134:1087-1095.
11. Lindberg C, Persson LI, Bjorkander J, et al.: Inclusion body myositis: clinical, morphologic, physiologic and laboratory findings in 18 cases. Acta Neurol Scan 1994, 89:123-131.
12. Rose MR, McDermott MP, Thornton CA, et al.: prospective natural history study of inclusion body myositis: implications for clinical trials. Neurol 2001, 57:548-550.
13. Peng A, Koffman BM, Malley JD, et al.: Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurol 2000, 55:296-298.
14. Engel AG, Hohlfield R, Banker BQ: Polymyositis and dermatomyositis. In Myology, edn 2. Edited by Engel AG, Franzini-Armstrong C. New York: McGraw-Hill, 1994: 1335-1383.
15. O'Hanlon TP, Dalakas MC, Plotz PH, et al.: The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun 1994, 7:321-333.
16. Lindberg C, Oldfors A, Tarkowski A: Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur J Immunol 1994, 24:2659-2663.
17. Lotz B, Engel AG, Nishino H, et al.: Inclusion body myositis: observations in 40 patients. Brain 1989, 112:727-747.
18. Amemiya K, Dalakas MC: The T-cell receptor repertoire of endomysial lymphocytes in patients with inclusion body myositis (IBM) remains restricted over time: studies in repeated muscle biopsies. Neurology 1998, 50:A204.
19. Pruitt JN, Showalter CJ, Engel AG: Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996, 39:139-143.
20. Amato AA, Shebert RT: Inclusion body myositis in twins. Neurology 1998, 51:598-600.
21. Santorelli FM, Sciacco M, Tanji K, et al.: Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol 1996, 39:789-795.
22. Oldfors A, Larsson NG, Lindberg C, et al.: Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. Biochim Biophys Acta 1992, 1180:113-122.
23. Karpati G: Inclusion body myositis: status 1997. The Neurologist 1997, 3:201-208.
24. Mendell JR, Sahenk Z, Gales T, et al.: Amyloid filaments in inclusion body myositis: novel findings provide insight into nature of filaments. Arch Neurol 1991, 48:1229-1234.
25. Sarkozi B, Askanas V, Engel WK: Abnormal accumulations of prion protein mRNA in muscle fibers of patients with sporadic inclusion body myositis and hereditary inclusion body myopathy. Am J Pathol 1994, 145:1280-1284.
26. Askanas V, Engel WK, Bilak M, et al.: Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain containing hyperphosphorylated tau. Am J Pathol 1994, 144:177-187.
27. Yang CC, Alvarez RB, Engel WK, et al.: Nitric oxide induced oxidative stress in the muscle fibers of hereditary inclusion body myopathy and sporadic inclusion body myositis. Neurology 1997, 48:A331.
28. Askanas V, Engel WK: Sporadic inclusion body myositis and its similarities to Alzheimer disease brain. Scand J Rheumatol 1998, 27:389-405.
29. Banwell BL, Engel AG: AB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurol 2000, 54:1033-1040.
30. Dalakas MC, Sonies B, Dambrosia J, et al.: Treatment of inclusion body myositis with IVIG: a double blind, placebo controlled study. Neurology 1997, 48:712-716.
31. Cherin P, Pelletier S, Teixeira A, et al.: Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurol 2002, 58:326.
32. Chabot S, Williams G, Yong VW: Microglial production of TNF-alpha is induced by activated T lymphocytes: involvement of VLA-4 and inhibition by interferon beta-1 b. J Clin Invest 1997, 100:604-612.
33. Toepfer M, Lochmuller H, Hirschmann M, et al.: Expression of chemokines in normal muscle and inflammatory mypathies. Neurology 1998, 50:A413.
34. The Muscle Study Group. Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis. Neurol 2001, 57:1583-1588.
35. Rutkow SB, Parker RA, Nardin RA, et al.: A pilot randomized trial of oxandrolone in inclusion body myositis. Neurol 2002, 58:1081-1087.
36. Mowzoon N, Sussman A, Bradley WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci 2001, 185:119-122.